Atamparib is under clinical development by Ribon Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Atamparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Atamparib overview

Atamparib (RBN-2397) is under development for the treatment of advanced squamous non-small cell lung carcinoma, squamous cell carcinoma of the lung, mantle cell lymphoma, HER2 negative breast cancer, head and neck squamous cell carcinoma and other solid tumors. It is administered by oral route as tablet formulation. The drug candidate is a new chemical entity. The drug candidate acts by targeting monoPARPs (poly ADP-ribose polymerases) PARP7. 

Ribon Therapeutics overview

Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions. The company leverages a chemical biology approach and its proprietary discovery platform for building a pipeline of small molecule inhibitors to numerous NAD+ utilizing enzymes includes monoPARPs, which have applications across multiple therapeutic areas. Its lead program is developing PARP7 inhibitors for the treatment of cancer. Ribon Therapeutics explores novel areas of disease biology and enzyme families for drug discovery and development of new treatments for patients with high unmet needs. The company is funded by including The Column Group, life science investors, U.S. Venture Partners, Deerfield Management and Osage University Partners. Ribon Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Atamparib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.